Monthly Archives: February 2007

Rebutting Novratis

As mentioned in Case Study II of the previous article on pharmaceutical patenting, Novartis obtained US patent 6894051 on 17 May 2005 for a new crystalline form of its blockbuster blood cancer drug Gleevec/Glivec. This crystal modification was termed the … Continue reading

Posted in Uncategorized | Leave a comment